A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Amelparib (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Jeil Pharmaceutical
- 14 Nov 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 14 Nov 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 02 Mar 2017 New trial record